Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Henry Ford Health System
Summary
Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD
Eligibility
- Age range
- 18–75 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Patients with AML/MDS/MPN, CMML post Allogeneic SCT who experience any drop in total or myeloid chimerism any time after day 30, or their day 30 or day100 myeloid donor chimerism is below 98% without concurrent hematologic relapse (that is, patients with \<5% bone marrow blasts as obtained at that time point) will be offered treatment with azacitidine 2. \>=30 -180 days post SCT and patients must have ANC\> 1000, PLT \> 50,000 3. Age 18-75 years old 4. Performance score of at least 70% by Karnofsky 5. Adequate kidney and liver function as demonstrated by: 1. Creatin…
Interventions
- Drugazacitidine
azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated
Location
- Henry ford hospitalDetroit, Michigan